MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer

Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation

(2011) Mingxuan Xia et al.   CELL CYCLE

MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer

(2010) Oskar W Rokhlin et al.   CANCER BIOLOGY & THERAPY

Update on castrate-resistant prostate cancer: 2010

(2010) Kiran Lassi et al.   CURRENT OPINION IN ONCOLOGY

Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone

(2009) J.P. Michiel Sedelaar et al.   PROSTATE

Nutlin-3a Activates p53 to Both Down-regulate Inhibitor of Growth 2 and Up-regulate mir-34a, mir-34b, and mir-34c Expression, and Induce Senescence

(2008) K. Kumamoto et al.   CANCER RESEARCH

Mechanisms mediating androgen receptor reactivation after castration

(2008) Xin Yuan et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS